ARID1A and lymphoma: Importantly, lymphoma cells with ARID1A loss (het and KO) exhibited significantly reduced susceptibility to CD19-CAR T cell-mediated killing, while re-expression of ARID1A in ARID1Ahet cells restored CAR T cell toxicity (Fig. 5H).